Abstract 2818
Background
We investigated the impact of secondary surgery (2Surg) after a first R1 or R2 resection in the 10931 pts with STS of the limb or trunk wall included in the nationwide NETSARC database from 2010 to 2017.
Methods
NETSARC (netsarc.org) is a network of 26 reference sarcoma centers with specialized multidisciplinary tumor boards (MDT), funded by the French NCI (INCa). Since 2010, presentation to an MDTB and second pathological review are mandatory for sarcoma pts. Statistics were performed with SPSS23.0. LRFS, metastasis-free survival (MFS), OS compared with the logrank test.
Results
In 5295 (49.4%) patients, sarcoma were located on the lower limb, 3670 (33.6%) on trunk wall, 1966 (18.0%) on upper limb. Local RFS (LRFS) and RFS (p < 0.001), but not OS, were superior for pts operated in a NETSARC center (N = 4417, 41%). LRFS & OS were best for pts presented to a Netsarc MDT (NMDT) AND who were first operated in NETSARC centers; while the worst LRFS & OS were observed in pts presented in a NMDT but first operated outside a NetSARC center (p < 0.001). Among the 2081 pts with a first R1 resection in whom 2Surg was documented, 1047 (50.3%) were reoperated. These R1 reoperated pts had a superior LRFS, metastatic free survival (MFS) and OS (p < 0.001): LRFS (p < 0.001), MFS (p = 0.05) and OS (p < 0.001) were superior after 2Surg only in pts operated 1st outside a Netsarc center. There were 823 pts with a first surgery with R2 resection in whom 2Surg was documented: 619 (75.2%) were reoperated. R2 reoperated patients had a superior LRFS and OS (p = 0.01). MFS was not different. Again, LRFS (p < 0.001) & OS (p < 0.001) were superior after 2Surg only in pts operated 1st outside a Netsarc center. Among reoperated pts, those for whom 2Surg was in a NetSARC center had a superior LRFS & RFS (p < 0.001) and OS (p = 0.05).
Conclusions
In this nationwide series of limb or trunk wall STS, 2Surg after a R1 or R2 primary excision was associated with an improved OS only when pts had been operated first outside a reference center. 2Surg in a NETSARC center was associated with a better OS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jean-Yves Blay.
Funding
INCA (NetSarc, RREPS, RESOS, LYRICAN (INCA-DGOS-INSERM 12563), ARC fundation, Ligue de L’Ain contre le Cancer, INCA (NetSARC, RREPS, RESOS and LYRICAN (INCA-DGOS-INSERM 12563), InterSARC), La Ligue contre le Cancer, Ligue de L’Ain contre le Cancer, la Fondation ARC, EURACAN (EC 739521).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5826 - Impact of abstention of diagnostic biopsy in sarcoma
Presenter: Armelle Dufresne
Session: Poster Discussion – Sarcoma
Resources:
Abstract
4087 - EURO-B.O.S.S.: Outcome in rare non-osteosarcoma bone sarcoma
Presenter: Peter Reichardt
Session: Poster Discussion – Sarcoma
Resources:
Abstract
1363 - Trabectedin with concurrent low-dose of radiation therapy for metastatic soft tissue sarcomas: A phase II trial of Spanish, French and Italian sarcoma groups
Presenter: Javier Martin Broto
Session: Poster Discussion – Sarcoma
Resources:
Abstract
1399 - Phase 1 combination dose-finding/phase 2 expansion cohorts of lenvatinib + etoposide + ifosfamide in patients (pts) aged 2 to _25 years with relapsed/refractory (r/r) osteosarcoma
Presenter: Nathalie Gaspar
Session: Poster Discussion – Sarcoma
Resources:
Abstract
1884 - A Phase II Study of Pazopanib as Front-Line Therapy in Patients with Non-resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
Presenter: Angela Hirbe
Session: Poster Discussion – Sarcoma
Resources:
Abstract
3492 - Immune classification of soft tissue sarcoma predicts clinical outcome
Presenter: Florent Petitprez
Session: Poster Discussion – Sarcoma
Resources:
Abstract
3452 - Unravelling omics landscape and targeting oncogenic pathways in undifferentiated pleomorphic sarcomas (UPS)
Presenter: Maud Toulmonde
Session: Poster Discussion – Sarcoma
Resources:
Abstract
Poster Discussion – Sarcoma - Invited Discussant 1672PD, 1673PD and 1675PD
Presenter: Andrew Hayes
Session: Poster Discussion – Sarcoma
Resources:
Slides
Webcast
Poster Discussion – Sarcoma - Invited Discussant 1674PD, 1676PD and 1677PD
Presenter: Emanuela Palmerini
Session: Poster Discussion – Sarcoma
Resources:
Slides
Webcast
Poster Discussion – Sarcoma - Invited Discussant 1678PD and 1679PD
Presenter: Hans-Ulrich Schildhaus
Session: Poster Discussion – Sarcoma
Resources:
Slides
Webcast